Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by and welcome to the Connexa Pharmaceuticals Second Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. If your question has been answered and you'd like to remove yourself from the queue, simply press star 11 again. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Jonathan Kirshenbaum, Investor Relations. Please go ahead, sir. Thank you, operator. Good morning, everyone, and welcome to the Canixa Pharmaceuticals second quarter 2026 earnings call. A press release highlighting our financial results and recent portfolio execution can be found on our website under the Investors section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction that will be followed by Ross Moat, our Chief Operating Officer, who will provide an update on Arculus commercial execution. From there, Connexa's Chief Medical Officer, Dr. John Paolini, will review our KPL387 development program and the ongoing Phase 2-3 clinical trial in recurrent pericarditis. After that, Mark Ragosa, our Chief Financial Officer, will review our second quarter 2026 financial results. And finally, Sanj will share closing remarks and kick off the Q&A session. Before getting started, Please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from such statements. A review of these statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contain...